WHITEHOUSE STATION, N.J. (AP) ¿ Merck & Co. and Santarus Inc. said Tuesday the Food and Drug Administration approved Merck's over-the-counter version of the Santarus prescription heartburn drug Zegerid. San Diego-based Santarus had partnered with Schering-Plough Corp. on the over-the-counter version, and stands to receive a $20 million milestone payment based on the approval. It could also get up to $37.5 million in sales milestone payments, along with royalties on sales. Merck said Zegerid OTC will be available in the first half of 2010. The drug will be sold by the Schering-Plough Health Care Products division, which Merck acquired in November as part of its acquisition of the drug maker. The drug, which combines omeprazole and sodium bicarbonate, is intended to prevent heartburn by suppressing stomach acid for 24 hours. In aftermarket trading, Santarus stock jumped $1.44, or 33.6 percent, to $5.73. The stock rose 7.5 percent during the day to close at $4.29, and reached a 52-week high of $4.39 in intraday trading.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Food & Drink
Beyond Meat Slides After Andrew Left's Citron Slams Stock in Tweet
Newly public meat-alternative company sees shares lower on short-seller's critique.
PepsiCo Still Looks Bullish - A Higher Price Target Seen
How do the charts look with their latest advance?
Del Monte Foods Targets Amazon Generation With New Products
CEO Greg Longstreet sat down with TheStreet to discuss how his company is adapting to changing consumer habits.
Is Beyond Meat's Rapid Run a Sign of an IPO-Driven Bubble?
Whether you're vegan or not, Beyond Meat's valuation is certainly hard to swallow at this point and its making the 2019 IPO picture somewhat unpalatable overall.